免疫球蛋白E型自身抗体在自身免疫相关皮肤病中的研究进展

doi:10.35541/cjd.20190922

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (6): 553-556.doi: 10.35541/cjd.20190922

• 综述 • 上一篇

免疫球蛋白E型自身抗体在自身免疫相关皮肤病中的研究进展

梁高澎宋志强

陆军军医大学西南医院皮肤科，重庆 400038

收稿日期:2019-09-23 修回日期:2020-05-22 发布日期:2021-05-31
通讯作者: 宋志强 E-mail:drsongzq@hotmail.com
基金资助:
国家自然科学基金（81673059）

Role of immunoglobulin E autoantibodies in autoimmune skin diseases

Liang Gaopeng, Song Zhiqiang

Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing 400038, China

Received:2019-09-23 Revised:2020-05-22 Published:2021-05-31
Contact: Song Zhiqiang E-mail:drsongzq@hotmail.com
Supported by:
National Natural Science Foundation of China（81673059）

摘要/Abstract

摘要： 【摘要】大量研究显示，免疫球蛋白E（IgE）不但参与变态反应的发生发展，还可通过多种机制诱发和加重自身免疫反应。IgE型自身抗体已证实可在多种自身免疫相关皮肤病中出现，可能通过与自身抗原结合影响树突细胞、肥大细胞、嗜碱性粒细胞等多种免疫机制参与相关疾病的发生发展。本文综述IgE在系统性红斑狼疮、大疱性类天疱疮以及慢性特发性荨麻疹等自身免疫相关皮肤病的诱发和加重中所起的作用和可能机制，为临床诊治提供理论基础。

关键词: 免疫球蛋白E, 自身免疫性疾病, 红斑狼疮, 系统性, 类天疱疮, 大疱性, 慢性特发性荨麻疹, IgE型自身抗体

Abstract: 【Abstract】 A large number of studies have shown that immunoglobulin E （IgE） not only participates in the occurrence and development of allergic reactions, but also induces and aggravates autoimmune reactions through various mechanisms. IgE autoantibodies have been confirmed to be present in a variety of autoimmune skin diseases, and may be involved in the occurrence and development of related diseases by affecting multiple immune cells such as dendritic cells, mast cells, and basophils via binding to autoantigens. This review summarizes the role and possible mechanism of action of IgE in the induction and exacerbation of autoimmune skin diseases such as systemic lupus erythematosus, bullous pemphigoid and chronic idiopathic urticaria, and provides a theoretical basis for clinical diagnosis and treatment.

Key words: Immunoglobulin E, Autoimmune diseases, Lupus erythematosus, systemic, Pemphigoid, bullous, Chronic idiopathic urticaria, IgE autoantibodies

梁高澎宋志强. 免疫球蛋白E型自身抗体在自身免疫相关皮肤病中的研究进展[J]. 中华皮肤科杂志, 2021,54(6):553-556. doi:10.35541/cjd.20190922

Liang Gaopeng, Song Zhiqiang. Role of immunoglobulin E autoantibodies in autoimmune skin diseases[J]. Chinese Journal of Dermatology, 2021, 54(6): 553-556.doi:10.35541/cjd.20190922

参考文献 30

［1］	Sanjuan MA, Sagar D, Kolbeck R. Role of IgE in autoimmunity［J］. J Allergy Clin Immunol, 2016,137（6）:1651⁃1661. doi: 10. 1016/j.jaci.2016.04.007.
［2］	Lin K, Xu W, Li W, et al. Establishment of a novel quantum dots⁃encoded microbead⁃based flow cytometric method for quantification of soluble FcεRIα in serum［J］. Cytometry A, 2017,91（7）:686⁃693. doi: 10.1002/cyto.a.23128.
［3］	Dema B, Pellefigues C, Hasni S, et al. Autoreactive IgE is prevalent in systemic lupus erythematosus and is associated with increased disease activity and nephritis［J/OL］. PLoS One, 2014,9（2）:e90424. doi: 10.1371/journal.pone.0090424.
［4］	Henault J, Riggs JM, Karnell JL, et al. Self⁃reactive IgE exacerbates interferon responses associated with autoimmunity［J］. Nat Immunol, 2016,17（2）:196⁃203. doi: 10.1038/ni.3326.
［5］	Brilland B, Scherlinger M, Khoryati L, et al. Platelets and IgE: shaping the innate immune response in systemic lupus erythematosus［J］. Clin Rev Allergy Immunol, 2020,58（2）:194⁃212. doi: 10.1007/s12016⁃019⁃08744⁃x.
［6］	Kamata A, Kurihara Y, Funakoshi T, et al. Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results［J］. Br J Dermatol, 2020,182（5）:1221⁃1227. doi: 10.1111/bjd.18364.
［7］	van Beek N, Schulze FS, Zillikens D, et al. IgE⁃mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases［J］. Expert Rev Clin Immunol, 2016,12（3）:267⁃277. doi: 10.1586/1744666X.2016.1123092.
［8］	Ujiie H. IgE autoantibodies in bullous pemphigoid［J］. Br J Dermatol, 2017,177（6）:1481⁃1482. doi: 10.1111/bjd.16034.
［9］	van Beek N, Lüttmann N, Huebner F, et al. Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity［J］. JAMA Dermatol, 2017,153（1）:30⁃38. doi: 10.1001/jamadermatol.2016.3357.
［10］	Schmetzer O, Lakin E, Topal FA, et al. IL⁃24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2018,142（3）:876⁃882. doi: 10.1016/j.jaci.2017.10.035.
［11］	Hatada Y, Kashiwakura J, Hayama K, et al. Significantly high levels of anti⁃dsDNA immunoglobulin E in sera and the ability of dsDNA to induce the degranulation of basophils from chronic urticaria patients［J］. Int Arch Allergy Immunol, 2013,161 Suppl 2:154⁃158. doi: 10.1159/000350388.
［12］	Kolkhir P, Metz M, Altrichter S, et al. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review［J］. Allergy, 2017,72（10）:1440⁃1460. doi: 10. 1111/all.13182.
［13］	Furue M, Chiba T, Tsuji G, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies［J］. Allergol Int, 2017,66（3）:398⁃403. doi: 10.1016/j.alit.2016.12.002.
［14］	Augusto JF, Truchetet ME, Charles N, et al. IgE in lupus pathogenesis: friends or foes?［J］. Autoimmun Rev, 2018,17（4）:361⁃365. doi: 10.1016/j.autrev.2017.11.027.
［15］	Miyamoto D, Santi CG, Aoki V, et al. Bullous pemphigoid［J］. An Bras Dermatol, 2019,94（2）:133⁃146. doi: 10.1590/abd1806⁃4841.20199007.
［16］	Schmidt E, Zillikens D. Pemphigoid diseases［J］. Lancet, 2013,381（9863）:320⁃332. doi: 10.1016/S0140⁃6736（12）61140⁃4.
［17］	Maurer M, Metz M, Magerl M, et al. Autoreactive urticaria and autoimmune urticaria［J］. Hautarzt, 2004,55（4）:350⁃356. doi: 10.1007/s00105⁃004⁃0692⁃9.
［18］	Ertas R, Ozyurt K, Atasoy M, et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change［J］. Allergy, 2018,73（3）:705⁃712. doi: 10.1111/all.13345.
［19］	Vollono L, Piccolo A, Lanna C, et al. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real⁃life clinical practice［J］. Drug Des Devel Ther, 2019,13:3181⁃3186. doi: 10.2147/DDDT.S214307.
［20］	Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know［J］. J Allergy Clin Immunol, 2017,139（6）:1772⁃1781.e1. doi: 10.1016/j.jaci.2016.08.050.
［21］	Tonacci A, Billeci L, Pioggia G, et al. Omalizumab for the treatment of chronic idiopathic urticaria: systematic review of the literature［J］. Pharmacotherapy, 2017,37（4）:464⁃480. doi: 10.1002/phar.1915.
［22］	Navinés⁃Ferrer A, Serrano⁃Candelas E, Molina⁃Molina GJ, et al. IgE⁃related chronic diseases and anti⁃IgE⁃based treatments［J］. J Immunol Res, 2016,2016:8163803. doi: 10.1155/2016/8163803.
［23］	Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria［J］. Allergy, 2018,73（7）:1393⁃1414. doi: 10.1111/all.13397.
［24］	Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI⁃positive cells in the skin［J］. Theranostics, 2017,7（5）:1266⁃1276. doi: 10.7150/thno.18304.
［25］	Kolkhir P, Altrichter S, Munoz M, et al. New treatments for chronic urticaria［J］. Ann Allergy Asthma Immunol, 2020,124（1）:2⁃12. doi: 10.1016/j.anai.2019.08.014.
［26］	Hasni S, Gupta S, Davis M, et al. Safety and tolerability of omalizumab: a randomized clinical trial of humanized anti⁃IgE monoclonal antibody in systemic lupus erythematosus［J］. Arthritis Rheumatol, 2019,71（7）:1135⁃1140. doi: 10.1002/art. 40828.
［27］	Seyed Jafari SM, Gadaldi K, Feldmeyer L, et al. Effects of Omalizumab on FcεRI and IgE expression in lesional skin of bullous pemphigoid［J］. Front Immunol, 2019,10:1919. doi: 10.3389/fimmu.2019.01919.
［28］	Holm JG, Agner T, Sand C, et al. Omalizumab for atopic dermatitis: case series and a systematic review of the literature［J］. Int J Dermatol, 2017,56（1）:18⁃26. doi: 10.1111/ijd.13353.
［29］	Chan S, Cornelius V, Cro S, et al. Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial［J］. JAMA Pediatr, 2019,174（1）:29⁃37. doi: 10. 1001/jamapediatrics.2019.4476.
［30］	El⁃Qutob D. Off⁃label uses of omalizumab［J］. Clin Rev Allergy Immunol, 2016,50（1）:84⁃96. doi: 10.1007/s12016⁃015⁃8490⁃y.

[1]	李锁向睿宇李志量荆可王媛张寒梅冯素英. 盐裂皮肤间接免疫荧光技术在大疱性类天疱疮诊断中的价值评估[J]. 中华皮肤科杂志, 2022, 55(3): 235-237.
[2]	李浩, 王俐韩宪伟孙彤苏芳孙晓冬韩莹杨国玲刘晓明王凯波 . 糖尿病患者服用二肽基肽酶Ⅳ抑制剂后发生大疱性类天疱疮32例临床特征分析[J]. 中华皮肤科杂志, 2022, 55(3): 213-218.
[3]	胡枫, 王向东, 夏云, 周小勇, 陈柳青. 国内首报落叶型天疱疮转变为大疱性类天疱疮1例[J]. 中华皮肤科杂志, 2022, 55(2): 156-158.
[4]	赵文玲, 杨语嫣, 李丽, 晋红中. 大疱性类天疱疮合并其他免疫性疾病研究进展[J]. 中华皮肤科杂志, 2022, 55(2): 177-181.
[5]	尹光文耿朦朦崔燕张守民李冬芹程秀永. 中国大陆首例新生儿线状IgA大疱性皮病[J]. 中华皮肤科杂志, 2022, 0(2): 20210502-e20210502.
[6]	李越吴金燕袁若月杨屈杨赵贤省朱宁文. 细胞治疗遗传性大疱性表皮松解症研究进展[J]. 中华皮肤科杂志, 2022, 0(1): 20201116-e20201116.
[7]	王媛余美文向睿宇李锁李志量荆可张寒梅冯素英. 盐裂皮肤-间接免疫荧光方法优化及在大疱性类天疱疮抗体检测中的应用[J]. 中华皮肤科杂志, 2022, 55(1): 12-15.
[8]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. 自身免疫性表皮下大疱病诊疗共识（2022）[J]. 中华皮肤科杂志, 2022, 55(1): 1-11.
[9]	龙海蒋丽邱月棨姚南刘力聪谢昱明熊峰谭思齐匡琪琪尤睿璇柴可罗鑫龙浩君忻悦郭子瑜王佳琪谭怡忻张庆张桂英李亚萍苏玉文肖嵘陆前进, . 皮肤科病房危重症1 057例临床分析[J]. 中华皮肤科杂志, 2021, 54(9): 790-797.
[10]	中国医师协会皮肤科医师分会自身免疫性疾病学组. 环磷酰胺治疗自身免疫性皮肤病中国专家共识[J]. 中华皮肤科杂志, 2021, 54(9): 765-770.
[11]	罗帅寒天龙海陆前进. 2020年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021, 54(6): 542-545.
[12]	中国医师协会皮肤科医师分会自身免疫病专业委员会. 甲氨蝶呤治疗免疫相关性皮肤病专家共识[J]. 中华皮肤科杂志, 2021, 54(5): 382-390.
[13]	渠莉田苏惠春程波. 特应性皮炎与系统性疾病相关性的研究进展[J]. 中华皮肤科杂志, 2021, 54(5): 463-466.
[14]	王小坡陈志明杨勇孙建方. KRT5基因新生突变致重度型单纯型大疱性表皮松解症一家系[J]. 中华皮肤科杂志, 2021, 54(3): 229-231.
[15]	万立, 刘美娜, 陈金波陈柳青. 利格列汀相关的BP230型大疱性类天疱疮一例国内首报[J]. 中华皮肤科杂志, 2021, 54(2): 136-138.

免疫球蛋白E型自身抗体在自身免疫相关皮肤病中的研究进展

Role of immunoglobulin E autoantibodies in autoimmune skin diseases

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

Metrics

本文评价

推荐阅读 10